Arcellx Inc to Host Investor Relations Event Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Asthika Goonewardene - Truist Securities - Analyst : Asthika from Truist. Just talk a little bit about ALC monitoring for a second here. So in the discussion today in the morning, feedback was that it might not just be enough to look at the absolute lymphocyte level, but you also need to look at how quickly the cells are increasing. The presenter from Stanford suggested that they are only monitoring ALC every 24 hours, and that might not be sufficient to capture the ALC growth rate. So to the 3 doctors on the panel here, how often do you currently monitor for it? And what actually do you need if you need to actually try and capture that growth rate as one of the indicators that you might be expose the patients to DLTs?

Question: Asthika Goonewardene - Truist Securities - Analyst : And then if I can ask, a lot has emerged over the last couple of years about sequencing bispecific and CAR-T. So with what you know today, if you say you had a patient who's seen a BCMA T-cell engager and it's been six months since they've been treated with that BCMA T-cell engager, would you consider giving that patient anito-cel?